|
|
Vaccine Detail
|
MART-1 Adenovirus Vaccine |
| Vaccine Information |
- Vaccine Name: MART-1 Adenovirus Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007502
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: MLANA (NCIT_C2773)
- MLANA-Dupli
gene engineering:
- Description: A vaccine consisting of recombinant adenovirus vector encoding MART-1 (melanoma antigen recognized by T-cells 1), an immunogenic protein of unknown function that is expressed by certain types of melanoma. Vaccination with MART-1 adenovirus vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against MART-1 positive melanoma cells, resulting in an antitumor effect. (NCI04) (NCIT_C2773).
|
| Host Response |
|
|
| References |
Butterfield et al., 2008: Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(3); 294-309. [PubMed: 18317358].
NCIT_C2773: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2773]
|
|
